Alzheimer’s Disease and Sleep Disorders: A Descriptive Study of Actigraphic and Clinical Presentation Based on Neuropsychiatric Inventory

Research Article

Austin Alzheimers J Parkinsons Dis. 2015;2(1): 1019.

Alzheimer’s Disease and Sleep Disorders: A Descriptive Study of Actigraphic and Clinical Presentation Based on Neuropsychiatric Inventory

Camargos EF1,2*, Scoralick FM³, Louzada LL¹, Quintas JL¹ and Nóbrega OT1,3

¹Programa de Pós-Graduação em Ciências Médicas,Universidade de Brasilia, Brasil

²Hospital Universitário de Brasília, Universidade de Brasilia, Brasil

³Programa de Pós–Graduação em Ciências da Saúde, Universidade de Brasilia, Brasil

*Corresponding author: Camargos EF, Endereço: Campus Universitário Darcy Ribeiro, Asa Norte, Brasília – DF, 70910-900, Brazil

Received: January 21, 2015; Accepted: July 14, 2015; Published: July 18, 2015


Sleep disorders are very common in Alzheimer’s disease. This study describes the clinical and actigraphic aspects of the sleep pattern of 41 Alzheimer’s disease patients identified with sleep disorders by means of the neuropsychiatric inventory. The clinical protocol used to assess sleep quality included eight categories of sleep complaints. In addition, each caregiver rated his/her own distress level according to a five-point scale. The most common primary sleep disorders found among elderly participants were: to wake caregivers during the night (n = 39; 95.1%) and to get up during the night (n = 33; 80.4%). Actigraphic measures confirmed the clinical observation with the nighttime total sleep time = 311.2 ± 91.6 minutes, awakenings = 25.9 ± 8.7 per night and nighttime wake after sleep onset = 198.5 ± 78.4 minutes. Subjects compensated the lack of sleep at night by sleeping and napping during the day: daytime total sleep time = 152.6 ± 97.3 minutes and naps = 32.2 ± 15.8 per day. Most caregivers (70.7%) rated their distress level as moderate/extreme. The authors advocate that further studies and trials focused on the profile of patients, the methods described and types of sleep disorders should be carried out.

Keywords: Sleep disorders; Insomnia; Alzheimer’s disease; Neuropsychiatric evaluation; Outpatient care


Sleep disorders (SD) are very common in Alzheimer’s disease (AD) and studies have identified prevalence of up to 40% in many AD stages [1]. In addition, there is evidence that variance in the sleep– wake cycle directly influences the Aβ levels in the brain tissue [2].

Among the many types of sleep disorders, increased occurrence and length of nocturnal awakenings and increased frequency of daytime napping are the most frequent [3].

Two clinical trials have been recently conducted to examine possible changes in the sleep parameters of AD patients with SDs after use of either trazodone or mirtazapine compared to those using placebo [4,5]. The aim of this report is to describe the overal clinical and actigraphic aspects of the sleep pattern of subjects included in these two clinical trials and characterize the main sleep problems in AD patients, thus contributing to further studies.


Individuals were recruited among outpatients of the Geriatric Medical Centre of the University’s General Hospital from February 2010 to March 2014. This hospital is a reference center for the diagnosis and treatment of dementia in the Brazilian Federal District. The study was previously approved by the University of Brasilia Ethics Research Committee. Written informed consent was obtained from all participants.

The inclusion criteria were: age = 60 years; probable AD [6]; caregiver or family member able to provide informed consent and to follow the patient so to provide information on the study variables; presence of sleep disorders causing emotional distress to caregivers (score =1 in the neuropsychiatric inventory - NPI) [7]; regular use of medications for at least 4 weeks prior to the screening visit; possibility of placing an actigraph to a mobile upper limb. Exclusion criteria were the following: sleep disorders associated with acute illness, delirium or psychiatric disease; clinically significant movement disorder; severe agitation; unstable medical condition.

Patients were assessed by wrist actigraphy for a period of 7 to 9 days at baseline (to determine the sleep profile) and for 2 weeks during intervention (mirtazapine, trazodone or placebo). The first two trials were aimed at comparing pre- and post-intervention parameters, but only data of the first week (pre-intervention) were used.

The protocol used for the sleep quality clinical assessment included NPI (Nighttime Behavior item), which investigates the following aspects: “Does the patient have difficulty sleeping (not including if the patient simply gets up once or twice per night only to go to the bathroom and falls back asleep immediately)? Is he/she up at night? Does he/she wander at night, get dressed, or disturb your sleep?” Considering the questions above, the following categories were defined to classify the outcomes observed: 1) difficulty falling asleep; 2) getting up during the night; 3) awaking caregivers during the night; 4) wandering, pacing, or getting involved in inappropriate activities at night (nocturnal perambulation); 5) awaking too early in the morning; 6) other nighttime behaviors (sleep talking); 7)sleeping excessively during the day; 8) waking up at night, dressing and planning to go out; 8) caregiver distress. In addition, caregiver had to rate his/her own distress level according to a five-point scale from 0 - no distress, 1- minimal, 2 - mild, 3 - moderate, 4 - moderately severe, 5 - very severe or extreme distress [8].

The actigraphic results were based on the nocturnal period (defined as a continuous 12-h time period from 8:00 pm to 8:00 am) and daytime period (12-h diurnal period from 8:00 am to 8:00 pm). The following variables of patients were defined: 1) NTST - Nighttime total sleep time (in minutes); 2) WASO - Nighttime wakening after sleep onset (in minutes) up to final awakening; 3) Awakenings - Nighttime number of awakenings after sleep onset up to final awakening; 4) DTST - Daytime total sleep time (in minutes); 5) Naps - Number of daytime naps; 6) %Sleep - percentage of time asleep during the nocturnal period.

The actigraphs used in this study were Actiwatch® (Respironics, Inc.) and its software (Actiware®, version 5.59.0015, 2010). Actigraphs were used on participants’ non-dominant wrist and the following parameters were analyzed: 1) wake threshold selection = medium; 2) wake threshold value = 40; 3) sleep interval detection algorithm = 10 immobile minutes for sleep onset and sleep end. There is evidence of good correlation between actigraphy and polysomnography measures in patients with dementia and it is appropriately used for measuring sleep in intervention studies with Alzheimer’s disease patients [9].

Other scales applied for all patients were: Cornell Depression Scale [10]; Behavioral Pathology in Alzheimer’s Disease (BEHAVEAD) [11]; Clinical Dementia Rating (CDR) [12]; Katz Index of Independence in Activities of Daily Living [13].

Data processing and statistical analysis were performed using SAS v.9.2 Software (SAS Institute, Inc., 1999) with descriptive analyses expressed as mean values (and standard deviations) or proportions, when appropriate.


Forty-one subjects diagnosed with AD and SD were included in this study. The mean age of subjects was 81.4 ± 7.7 years, with women comprising 68.2% of the sample. The mean MMSE score of 11.0 ± 6.8 and the highly frequent CDR scores of 2 and 3 were compatible with moderate to severe dementia as the most common phenotypes. Demographic and descriptive variables are described in Table 1.

Citation: Patton D. Older Person Research in Ireland. Austin Alzheimers J Parkinsons Dis. 2015;2(1): 1018. ISSN: 2377-357X